22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell transplantation. However, literature about the influence of NK-DLI on recipient's immune system is scarce. Here we present concomitant results of a noninvasive in vivo monitoring approach of recipient's peripheral blood (PB) cells after transfer of either unstimulated (NK-DLI (unstim)) or IL-2 (1000 U/ml, 9–14 days) activated NK cells (NK-DLI (IL-2 stim)) along with their ex vivo secreted cytokine/chemokines. We performed phenotypical and functional characterizations of the NK-DLIs, detailed flow cytometric analyses of various PB cells and comprehensive cytokine/chemokine arrays before and after NK-DLI. Patients of both groups were comparable with regard to remission status, immune reconstitution, donor chimerism, KIR mismatching, stem cell and NK-DLI dose. Only after NK-DLI (IL-2 stim) was a rapid, almost complete loss of CD56 (bright)CD16 (dim/−) immune regulatory and CD56 (dim)CD16 (+) cytotoxic NK cells, monocytes, dendritic cells and eosinophils from PB circulation seen 10 min after infusion, while neutrophils significantly increased. The reduction of NK cells was due to both, a decrease in patients' own CD69 (−) NCR (low)CD62L (+) NK cells as well as to a diminishing of the transferred cells from the NK-DLI (IL-2 stim) with the CD56 (bright)CD16 (+/−)CD69 (+)NCR (high)CD62L (−) phenotype. All cell counts recovered within the next 24 h. Transfer of NK-DLI (IL-2 stim) translated into significantly increased levels of various cytokines/chemokines (i.e. IFN-γ, IL-6, MIP-1β) in patients' PB. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and/or extravasation. In contrast, NK-DLI (unstim) did not cause any of the observed effects. In conclusion, we assume that the adoptive transfer of NK-DLI (IL-2 stim) under the influence of ex vivo and in vivo secreted cytokines/chemokines may promote NK cell trafficking and therefore might enhance efficacy of immunotherapy.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          NK cell recognition.

          The integrated processing of signals transduced by activating and inhibitory cell surface receptors regulates NK cell effector functions. Here, I review the structure, function, and ligand specificity of the receptors responsible for NK cell recognition.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The trafficking of natural killer cells

            Summary: Natural killer (NK) cells are large granular lymphocytes of the innate immune system that participate in the early control of microbial infections and cancer. NK cells can induce the death of autologous cells undergoing various forms of stress, recognizing and providing non‐microbial ‘danger’ signals to the immune system. NK cells are widely distributed in lymphoid and non‐lymphoid organs. NK cell precursors originate from the bone marrow and go through a complex maturation process that leads to the acquisition of their effector functions, to changes in their expression of integrins and chemotactic receptors, and to their redistribution from the bone marrow and lymph nodes to blood, spleen, liver, and lung. Here, we describe the tissue localization of NK cells, using NKp46 as an NK cell marker, and review the current knowledge on the mechanisms that govern their trafficking in humans and in mice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prospects for the use of NK cells in immunotherapy of human cancer.

              Current insights into the molecular specificities that regulate natural killer (NK)-cell function suggest that it might be possible to design NK-cell-based immunotherapeutic strategies against human cancer. Here, we describe evidence for NK-cell targeting of human tumours and address crucial questions that, in our opinion, require consideration for the development of successful NK-cell-based therapies. Appropriately used, we predict that NK cells will have a role, both directly and in combination with other treatment modalities, in future treatment of cancer.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2011
                9 November 2011
                : 6
                : 11
                : e27351
                Affiliations
                [1 ]Pediatric Hematology and Oncology, Laboratory for Stem Cell Transplantation and Immunotherapy, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany
                [2 ]Institute for Transfusion Medicine and Immunohematology, Red Cross Blood Donor Service, Baden-Württemberg-Hessen, Frankfurt, Germany
                [3 ]Pharmazentrum Frankfurt, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany
                [4 ]Division of Hematology, University Hospital, Basel, Switzerland
                University of Palermo, Italy
                Author notes

                Conceived and designed the experiments: UK. Performed the experiments: CB SH AQ MB. Analyzed the data: CB SH AQ HM RE SK. Wrote the paper: CB UK. Patient enrollment: TK PB JS. Clinical study design: DS JRP UK. Chimerism analysis: HK PB. KIR/HLA genotyping: PSAB CS.

                Article
                PONE-D-11-09994
                10.1371/journal.pone.0027351
                3212563
                22096557
                0168c1a2-d477-4be6-83fc-ee81643e2fef
                Brehm et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
                History
                : 3 June 2011
                : 14 October 2011
                Page count
                Pages: 13
                Categories
                Research Article
                Biology
                Immunology
                Immune Cells
                NK cells
                Immune System
                Cytokines
                Medicine
                Clinical Immunology
                Immune Cells
                NK cells
                Immune System
                Cytokines
                Clinical Research Design
                Clinical Trials
                Hematology
                Bone Marrow and Stem Cell Transplantation
                Pediatric Hematology
                Oncology
                Cancer Treatment
                Immunotherapy
                Pediatric Oncology
                Pediatrics

                Uncategorized
                Uncategorized

                Comments

                Comment on this article